BE898540A - Procédé pour soulager les troubles moteurs extrapyramidaux. - Google Patents
Procédé pour soulager les troubles moteurs extrapyramidaux. Download PDFInfo
- Publication number
- BE898540A BE898540A BE0/212106A BE212106A BE898540A BE 898540 A BE898540 A BE 898540A BE 0/212106 A BE0/212106 A BE 0/212106A BE 212106 A BE212106 A BE 212106A BE 898540 A BE898540 A BE 898540A
- Authority
- BE
- Belgium
- Prior art keywords
- extrapyramidal
- disorders
- buspirone
- relieving
- mammal
- Prior art date
Links
- 208000019430 Motor disease Diseases 0.000 title claims abstract description 15
- 238000000034 method Methods 0.000 title claims abstract description 13
- QWCRAEMEVRGPNT-UHFFFAOYSA-N buspirone Chemical compound C1C(=O)N(CCCCN2CCN(CC2)C=2N=CC=CN=2)C(=O)CC21CCCC2 QWCRAEMEVRGPNT-UHFFFAOYSA-N 0.000 claims abstract description 25
- 229960002495 buspirone Drugs 0.000 claims abstract description 18
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 9
- 239000002253 acid Substances 0.000 claims abstract description 8
- 208000027776 Extrapyramidal disease Diseases 0.000 claims abstract description 7
- 150000003839 salts Chemical class 0.000 claims abstract description 7
- 208000027089 Parkinsonian disease Diseases 0.000 claims abstract description 6
- 206010034010 Parkinsonism Diseases 0.000 claims abstract description 6
- 241000124008 Mammalia Species 0.000 claims abstract 7
- 231100000252 nontoxic Toxicity 0.000 claims abstract 3
- 230000003000 nontoxic effect Effects 0.000 claims abstract 3
- 239000003176 neuroleptic agent Substances 0.000 claims description 8
- 229960001768 buspirone hydrochloride Drugs 0.000 claims description 7
- 230000000701 neuroleptic effect Effects 0.000 claims description 7
- 150000007513 acids Chemical class 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 abstract description 6
- 239000003814 drug Substances 0.000 abstract description 6
- 230000001747 exhibiting effect Effects 0.000 abstract 1
- 208000009132 Catalepsy Diseases 0.000 description 20
- 206010047853 Waxy flexibility Diseases 0.000 description 20
- 241001465754 Metazoa Species 0.000 description 17
- 230000000694 effects Effects 0.000 description 9
- 241000700159 Rattus Species 0.000 description 7
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 6
- 238000012360 testing method Methods 0.000 description 5
- 238000010171 animal model Methods 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 208000011580 syndromic disease Diseases 0.000 description 4
- 229960002324 trifluoperazine Drugs 0.000 description 4
- ZEWQUBUPAILYHI-UHFFFAOYSA-N trifluoperazine Chemical compound C1CN(C)CCN1CCCN1C2=CC(C(F)(F)F)=CC=C2SC2=CC=CC=C21 ZEWQUBUPAILYHI-UHFFFAOYSA-N 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 3
- 229960003638 dopamine Drugs 0.000 description 3
- WJFKNYWRSNBZNX-UHFFFAOYSA-N 10H-phenothiazine Chemical compound C1=CC=C2NC3=CC=CC=C3SC2=C1 WJFKNYWRSNBZNX-UHFFFAOYSA-N 0.000 description 2
- 208000019901 Anxiety disease Diseases 0.000 description 2
- 208000012902 Nervous system disease Diseases 0.000 description 2
- 208000025966 Neurological disease Diseases 0.000 description 2
- 230000036506 anxiety Effects 0.000 description 2
- 208000018300 basal ganglia disease Diseases 0.000 description 2
- 239000000812 cholinergic antagonist Substances 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 229950000688 phenothiazine Drugs 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 210000001364 upper extremity Anatomy 0.000 description 2
- 241000238876 Acari Species 0.000 description 1
- 102100038238 Aromatic-L-amino-acid decarboxylase Human genes 0.000 description 1
- 208000031872 Body Remains Diseases 0.000 description 1
- 208000009810 Catatonic Schizophrenia Diseases 0.000 description 1
- 241000557626 Corvus corax Species 0.000 description 1
- 208000012661 Dyskinesia Diseases 0.000 description 1
- 208000014094 Dystonic disease Diseases 0.000 description 1
- 208000035126 Facies Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical class Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 208000019468 Iatrogenic Disease Diseases 0.000 description 1
- 206010021703 Indifference Diseases 0.000 description 1
- 208000015592 Involuntary movements Diseases 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 description 1
- 206010052904 Musculoskeletal stiffness Diseases 0.000 description 1
- 208000036754 Schizophrenia, catatonic type Diseases 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 108010035075 Tyrosine decarboxylase Proteins 0.000 description 1
- ORILYTVJVMAKLC-UHFFFAOYSA-N adamantane Chemical compound C1C(C2)CC3CC1CC2C3 ORILYTVJVMAKLC-UHFFFAOYSA-N 0.000 description 1
- 229910001573 adamantine Inorganic materials 0.000 description 1
- 230000001078 anti-cholinergic effect Effects 0.000 description 1
- 229940065524 anticholinergics inhalants for obstructive airway diseases Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000164 antipsychotic agent Substances 0.000 description 1
- 229940005529 antipsychotics Drugs 0.000 description 1
- 239000002249 anxiolytic agent Substances 0.000 description 1
- 230000000949 anxiolytic effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- OZVBMTJYIDMWIL-AYFBDAFISA-N bromocriptine Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@]2(C(=O)N3[C@H](C(N4CCC[C@H]4[C@]3(O)O2)=O)CC(C)C)C(C)C)C2)=C3C2=C(Br)NC3=C1 OZVBMTJYIDMWIL-AYFBDAFISA-N 0.000 description 1
- 229960002802 bromocriptine Drugs 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000002903 catalepsic effect Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 239000013043 chemical agent Substances 0.000 description 1
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 1
- 229960003529 diazepam Drugs 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 230000003291 dopaminomimetic effect Effects 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 208000010118 dystonia Diseases 0.000 description 1
- 230000003100 immobilizing effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 230000017311 musculoskeletal movement, spinal reflex action Effects 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 230000001003 psychopharmacologic effect Effects 0.000 description 1
- 230000000506 psychotropic effect Effects 0.000 description 1
- 150000003230 pyrimidines Chemical class 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000021542 voluntary musculoskeletal movement Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US06/452,686 US4438119A (en) | 1982-12-23 | 1982-12-23 | Method for alleviation of extrapyramidal motor disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BE898540A true BE898540A (fr) | 1984-06-22 |
Family
ID=23797489
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BE0/212106A BE898540A (fr) | 1982-12-23 | 1983-12-22 | Procédé pour soulager les troubles moteurs extrapyramidaux. |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US4438119A (enExample) |
| JP (1) | JPS59130215A (enExample) |
| AU (1) | AU556112B2 (enExample) |
| BE (1) | BE898540A (enExample) |
| DE (1) | DE3346237A1 (enExample) |
| PH (1) | PH18968A (enExample) |
| ZA (1) | ZA839451B (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4634703A (en) * | 1985-10-25 | 1987-01-06 | Bristol-Myers Company | Method for alleviation of panic disorders |
| US4640921A (en) * | 1986-02-04 | 1987-02-03 | Bristol-Myers | Treatment of sexual dysfunction with buspirone |
| US4687772A (en) * | 1986-10-07 | 1987-08-18 | Bristol-Myers Company | Method for improvement of short term memory |
| US4777173A (en) * | 1987-03-25 | 1988-10-11 | Bristol-Myers Company | Method for treatment of alcohol abuse |
| DE3736974A1 (de) * | 1987-10-31 | 1989-05-11 | Troponwerke Gmbh & Co Kg | Verwendung von 2-pyrimidinyl-1-piperazin-derivaten |
| US5468749A (en) * | 1988-08-30 | 1995-11-21 | Gawin; Frank H. | Method for treatment of substance addiction |
| US6432956B1 (en) | 1990-02-12 | 2002-08-13 | William C. Dement | Method for treatment of sleep apneas |
| US5633009A (en) * | 1990-11-28 | 1997-05-27 | Sano Corporation | Transdermal administration of azapirones |
| US5824680A (en) * | 1991-08-31 | 1998-10-20 | Bayer Aktiengesellschaft | Ipsapirone for the treatment of alzheimer's disease by improving memory |
| US5484788A (en) * | 1993-03-26 | 1996-01-16 | Beth Israel Hospital Association | Buspirone as a systemic immunosuppressant |
| US5631017A (en) * | 1993-03-26 | 1997-05-20 | Beth Israel Deaconess Medical Center, Inc. | Topical application of buspirone for treatment of pathological conditions associated with immune responses |
| US5637314A (en) * | 1995-06-07 | 1997-06-10 | Beth Israel Deaconess Medical Center, Inc. | Topical and systemic application of buspirone or derivatives thereof for treating atopic dermatitis |
| UA73981C2 (en) * | 2000-03-10 | 2005-10-17 | Merck Patent Gmbh | (r)-(-)-2-[5-(4-fluorophenyl)-3-pyridylmethylaminomethyl]-chromane for treatment of extrapyramidal movement disorders (variants), pharmaceutical composition and kit |
| US7053092B2 (en) | 2001-01-29 | 2006-05-30 | Otsuka Pharmaceutical Co., Ltd. | 5-HT1a receptor subtype agonist |
| EP1408964B1 (en) * | 2001-07-26 | 2007-01-24 | MERCK PATENT GmbH | Use of 2- 5-(4-fluorophenyl)-3-pyridylmethylaminomethyl|-chromane and its physiologically acceptable salts |
| AR033485A1 (es) | 2001-09-25 | 2003-12-26 | Otsuka Pharma Co Ltd | Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma |
| GT200600414A (es) * | 2005-09-12 | 2007-09-20 | Sal de glucuranato de compuesto de piperazine | |
| GT200600416A (es) * | 2005-09-12 | 2007-09-20 | Sales salicilato y gentisato de un compuesto de piperazina | |
| PE20070523A1 (es) * | 2005-09-12 | 2007-06-28 | Wyeth Corp | Formulacion de liberacion sostenida del glucuronato de (8-{4-[3-(5-fluoro-1h-indol-3-il)-propil]-piperazin-1-il}-2-metil-4h-benzo[1,4]oxazin-3-ona |
| HRP20161402T1 (hr) * | 2010-10-15 | 2016-12-30 | Contera Pharma Aps | Kombinacije agonista serotoninskih receptora za liječenje poremećaja kretanja |
| ES2654787T3 (es) | 2012-04-18 | 2018-02-15 | Contera Pharma Aps | Formulación farmacéutica disponible por vía oral adecuada para la gestión mejorada de trastornos del movimiento |
| HUE039750T2 (hu) * | 2014-06-26 | 2019-02-28 | Contera Pharma Aps | Hidroxi-buspiron mozgászavarok kezelésére |
| WO2018011181A1 (en) | 2016-07-11 | 2018-01-18 | Contera Pharma Aps | Pulsatile drug delivery system for treating morning akinesia |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE759371A (fr) | 1969-11-24 | 1971-05-24 | Bristol Myers Co | Azaspirodecanediones heterocycliques et procedes pour leur preparation |
| US3976776A (en) | 1972-12-06 | 1976-08-24 | Mead Johnson & Company | Tranquilizer process employing N-(heteroarcyclic)piperazinylalkylazaspiroalkanediones |
| US4182763A (en) * | 1978-05-22 | 1980-01-08 | Mead Johnson & Company | Buspirone anti-anxiety method |
-
1982
- 1982-12-23 US US06/452,686 patent/US4438119A/en not_active Expired - Lifetime
-
1983
- 1983-12-20 ZA ZA839451A patent/ZA839451B/xx unknown
- 1983-12-21 DE DE19833346237 patent/DE3346237A1/de not_active Withdrawn
- 1983-12-22 BE BE0/212106A patent/BE898540A/fr not_active IP Right Cessation
- 1983-12-22 AU AU22793/83A patent/AU556112B2/en not_active Expired
- 1983-12-23 JP JP58242302A patent/JPS59130215A/ja active Granted
- 1983-12-23 PH PH30027A patent/PH18968A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PH18968A (en) | 1985-11-26 |
| US4438119A (en) | 1984-03-20 |
| AU556112B2 (en) | 1986-10-23 |
| ZA839451B (en) | 1984-09-26 |
| JPH0422889B2 (enExample) | 1992-04-20 |
| DE3346237A1 (de) | 1984-07-05 |
| JPS59130215A (ja) | 1984-07-26 |
| AU2279383A (en) | 1984-06-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BE898540A (fr) | Procédé pour soulager les troubles moteurs extrapyramidaux. | |
| DE60209504T2 (de) | Carbocyclische hydrazino-hemmer von kupferhaltigen aminoxidasen | |
| DK2278960T3 (en) | DOSAGE regimen for a selective SIP1 RECEPTOR AGONIST | |
| JP2022003085A (ja) | 神経変性疾患のための治療薬 | |
| EP2683376B1 (en) | Methods for treating diseases using isoindoline compounds | |
| CN110141663A (zh) | 通过控制血糖水平用于治疗糖尿病及相关病症的组合物、方法以及用途 | |
| JP7410055B2 (ja) | ニコチンアミドアデニンジヌクレオチド（ｎａｄ＋）前駆体及び少なくとも１種のケトン又はケトン前駆体を使用する組成物及び方法 | |
| JP2002538106A (ja) | イソバレルアミド、イソ吉草酸、または関連化合物を用いてｃｎｓ活性の調節に影響を与えることによる、痙縮および痙攣を含む様々な病状の治療 | |
| TW200845959A (en) | Use of prodrugs of GABA analogs for treating diseases | |
| LU81294A1 (fr) | Procede pour causer de l'anorecie par administration buccale de naltrexone ou d'un sel de celle-ci | |
| JP2006513977A (ja) | フェヌグリーク種子生物活性組成物およびその抽出法 | |
| EP4048263A1 (en) | Methods for treating neurological disorders with alpha 1a-ar partial agonists | |
| JP2012500801A (ja) | Ｃｎｓ疾患の治療法 | |
| CN1235541A (zh) | 用异戊酸衍生物类cns抑制剂治疗痉挛、惊厥 | |
| KR102549684B1 (ko) | 신경퇴행성 질병에 대한 치료제 | |
| CZ20013149A3 (cs) | Léčivo proti chronické obstrukční pulmonární chorobě a způsob jeho výroby | |
| JP2025160480A (ja) | 不眠症を治療するためのレンボレキサントの使用 | |
| RU2423981C2 (ru) | Фармацевтическая композиция для лечения болезни паркинсона | |
| JP2000513722A (ja) | 平滑筋鎮痙剤、それらを含有する組成物およびその使用方法 | |
| US20200323842A1 (en) | Carbamoyl cyclohexane derivatives for treating autism spectrum disorder | |
| JP2005501108A (ja) | 神経変性治療におけるネフィラセタムの使用 | |
| US6552087B1 (en) | Therapeutic agent comprising (+)-sibutramine | |
| JP4382480B2 (ja) | γ−ブチロベタインを含んで成る医薬組成物 | |
| US20060258708A1 (en) | Method for treating Parkinson's disease and other neurological diseases | |
| JPWO2006006617A1 (ja) | 中枢神経疾患発症後の機能障害の回復促進剤 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RE20 | Patent expired |
Owner name: *BRISTOL-MYERS CY Effective date: 20031222 |